Supernus Pharmaceuticals (SUPN) Equity Ratio (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Equity Ratio data on file, last reported at 0.72 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.72, down 6.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.72 (down 6.21% YoY), and the FY2025 annual result was 0.73, down 3.46% from the prior year.
• Equity Ratio eased to 0.72 in Q1 2026 per SUPN's latest filing, from 0.73 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.77 in Q2 2025 and troughed at 0.5 in Q2 2022.
• A 5-year average of 0.67 and a median of 0.72 in 2026 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2026: Equity Ratio surged 43.3% in 2023, then slipped 6.21% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.52 in 2022, then surged by 38.56% to 0.72 in 2023, then climbed by 4.97% to 0.76 in 2024, then dropped by 3.46% to 0.73 in 2025, then retreated by 1.83% to 0.72 in 2026.
• Business Quant data shows SUPN's Equity Ratio at 0.72 in Q1 2026, 0.73 in Q4 2025, and 0.74 in Q3 2025.